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ABSTRACT
Background:  Research has demonstrated the effectiveness of misoprostol for treatment 
of incomplete abortion. However, few studies have focused on the feasibility of treating 
incomplete abortion with misoprostol at the rural clinic level in sub-Saharan Africa.
Objective: To determine the effectiveness, safety and acceptability of misoprostol as 
an alternative to the surgical treatment of incomplete abortion at a rural clinic.
Design: Open-label randomised controlled trial.
Setting: A private clinic in Ekeakpara community, Osisioma Ngwa Local Government 
Area, Abia State, Nigeria.
Subjects: Women of reproductive age presenting with incomplete abortion.
Results: Regardless of treatment allocation, nearly all women had a complete uterine 
evacuation with either oral misoprostol or manual vacuum aspiration (misoprostol: 
98.8%, MVA: 100%, P = 0.99). Misoprostol users were more likely to report that they 
were ‘very satisfied’ with the method (75.6% versus 45%, P<0.001). In the 72 hours after 
treatment, women using misoprostol reported heavier bleeding but lower levels of 
pain than those treated with manual vacuum aspiration. Women in the misoprostol 
group were more likely to choose that treatment again (96.9 versus 55.6%; P<0.001) 
and would recommend it to a friend.
Conclusion: For treatment of first-trimester uncomplicated incomplete abortion at a 
rural facility, both MVA and 600 µg oral misoprostol are safe, effective, and acceptable 
treatments. Depending on availability of each method and the desires of individual 
women, either option may be presented to women for the treatment of incomplete 
abortion.
INTRODUCTION
Approximately one in five recognised pregnancies 
are spontaneously miscarried in the first trimester 
(1) and an additional 22% end in induced abortion 
(2). An incomplete abortion can result from either 
spontaneous or induced pregnancy loss and occurs 
when products of conception are not completely 
expelled from the uterus. Incomplete abortion is 
closely related to unsafe abortion in many parts of the 
world and continues to contribute disproportionately 
to maternal mortality and morbidity in sub-Saharan 
Africa (3). Safe and effective treatment for incomplete 
abortion is therefore an important way to reduce 
abortion-related morbidity and mortality, particularly 
in settings like Nigeria where legal abortion is 
restricted. Incomplete abortion can be treated with 
expectant management, which allows for spontaneous 
evacuation of the uterus, or active management, 
using surgical or medical methods. Expectant 
management is not preferred by many providers due 
to its relatively low efficacy and the fact that the time 
interval to spontaneous expulsion is unpredictable (4). 
Surgical methods are highly effective for treatment 
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of incomplete abortion. However, these treatments 
require trained providers, special equipment, sterile 
conditions and often anesthesia, all of which are 
limited in many rural facilities in low-resource settings 
(5). A review of the recent literature on misoprostol 
shows that it successfully completes expulsion in 
between 91 and 99% of women who receive it for 
incomplete abortion, inevitable and missed abortion 
in the first trimester (6-11). These studies which were 
conducted in Tanzania (6), Mozambique (8), Burkina 
Faso (9), Uganda (10) and Ghana (11) provided 
evidence that a single dose of 600µg oral misoprostol 
is as safe and effective as manual vacuum aspiration 
(MVA) when used for uterine evacuation. Majority of 
these researches, however, took place in tertiary-care 
facilities and regional hospitals. The present study 
was designed to fill an important gap in the research 
by testing misoprostol for incomplete abortion 
treatment at a small private clinic with a large rural 
catchment area in another resource-poor country in 
sub-Saharan Africa. 
                                     
MATERIALS AND METHODS
This was an open-label randomised trial to compare 
the safety,efficacy and acceptability of a single dose 
of 600µg misoprostol taken orally and MVA (the 
standard of care) for the treatment of incomplete 
abortion. 
 From January 2010 to December 2011, 320 
women were recruited at a private clinic with 
existing post-abortion care services and situated at 
Ekeakpara, a rural community in Osisioma Ngwa 
Local Government Area of Abia State, Nigeria. 
Osisioma Ngwa has a total area of 76 sq miles and 
a total population (2006 census) of 219,632 (12). 
An incomplete abortion was diagnosed by clinical 
history and examination; complete evacuation was 
assessed using the same set of clinical techniques. 
Eligibility criteria were open cervical os, vaginal 
bleeding or history of vaginal bleeding during this 
pregnancy, and uterine size of less than or equal to 12 
weeks’ LMP. Additional eligibility criteria included 
willingness to return for follow up in one week, no 
known contraindications to misoprostol, and general 
good health. Women were excluded if they had signs 
of severe infection (foul-smelling discharge, fever > 
38oC, or pulse > 110/minute), or known allergy to 
misoprostol or other prostaglandin, suspected ectopic 
pregnancy and haemodynamic instability or shock.
 Women who met the above criteria were given 
detailed information about the study and asked if 
they would like to participate. Consenting women 
were randomly assigned to one of the two study 
regimens. The randomisation allocation was 1:1 
(600µg misoprostol tablet taken orally: MVA) and 
was accomplished using sequentially numbered 
envelopes. When a new participant was enrolled 
in the study, a trained nurse would open the next 
envelope in the numbered series and the woman 
would receive the treatment specified therein.
 Women receiving misoprostol were counseled on 
the side effects of the drug and swallowed the pills 
in the presence of a trained nurse. Women allocated 
to MVA (Ipas, Chapel Hill, NC, USA) were given 
surgical evacuation by a trained doctor in the MVA 
room at the clinic using reassurance alone and no 
anaesthesia during the procedure. All participants, 
regardless of assigned treatment were given 
prophylactic antibiotics, and Paracetamol tablets to 
help manage their pain. They were observed in the 
clinic for a maximum of three hours after treatment 
and, in absence of danger signs, discharged. No 
admission was offered. The women and the study 
nurse exchanged phone numbers and they were told 
that they could contact the nurse at any time with 
any concerns.
 Each woman was requested to return to the 
hospital seven days after treatment. At the follow-
up visit, each woman’s abortion status was assessed 
clinically by an interview, a bimanual examination 
and speculum examination. If the abortion was 
found to be complete, the woman was released 
from the study. If the abortion was still incomplete, 
the woman was offered the choice between an 
additional follow-up visit in one week with no 
further intervention during the period or immediate 
surgical evacuation. If after the additional week of 
follow-up the abortion was still not complete, the 
woman underwent MVA. The study protocol did 
not call for routine ultrasound examination (either 
for initial diagnosis or for determination of treatment 
success) or administration of prophylactic antibiotics, 
or haemoglobin testing.
 The primary outcome measure was complete 
uterine evacuation after initial treatment (either 
misoprostol or MVA). Other outcome measures 
included adverse effects from the treatment assessed 
by observation and at an exit interview, where the 
participants were asked to report on the adverse 
effect they had experienced. Pain intensity and 
satisfaction was measured using a seven and five 
point Likert scale respectively (13). A visual analog 
scale using seven increasingly larger circles depicted 
on a card (the smallest equaling no pain, the largest 
the worst imaginable pain), was used to codify the 
pain they had in connection with their treatment. 
To further assess each woman’s satisfaction and the 
acceptability of the methods, each participant was 
asked to indicate whether she was satisfied, very 
satisfied or unsatisfied with the treatment and to 
indicate whether she would select the treatment 
again or recommend it to a friend. The participants’ 
responses to these questions were categorised and 
analysed quantitatively.  
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 Data entry and analysis were done using Epi 
Info 6.0 (U.S. Centers for Disease Control and 
Prevention Atlanta, GA). Chi-square tests were 
used for categorical data with Fisher exact or Yates 
correction where appropriate and t test was used 
to compare means. Statistical significance was 
defined as a P < 0.05.
 The study was conducted in accordance 
with the declaration of Helsinki – women were 
enrolled after counseling and informed consent, 
and the study was approved by the Ethics and 
Research Committee of Abia State University 
Teaching Hospital, Aba, Nigeria. All records were 
identified only by code number and initials to 
maintain confidentiality and locked in a filing 
cabinet. Women were assured that no clinical 
information would be released without their 
express permission. Assuming a 99% efficacy rate 
for MVA, the study was designed to have a 90% 
power to detect whether misoprostol was 6% less 
effective than MVA.                                                       
  RESULTS
A total of 320 women were enrolled, and 160 women 
were randomised into the misoprostol group and 
160 women into the MVA group (Figure 1). Each 
woman received the allocated treatment and no 
woman was lost to follow up. Table 1 details the 
characteristics of the study participants. There were 
no significant differences between women in the 
two groups. The average age of the participants was 
29 years and majority were married. More than 90% 
of the women indicated they were experiencing a 
spontaneous abortion, but many (> 25%) had had 
induced abortion in the past.
Figure1
Consort flow chart






Women recruited (n = 320)
Eligible (n = 320)
Allocated to MVA (n = 160)Allocated to misoprostol (n = 160)
Received allocated treatment (n = 160)Received allocated treatment (n = 160)
Analysed (n = 160)Analysed (n = 160)
Lost to follow-up (n =0)Lost to follow-up (n = 0)
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Table 1
Participant characteristics
Characteristic Misoprostol MVA P-value
 (N=160) (N=160)
Age, years (mean, SD) 29.0±8.2 29.0±8.3 0.84*
Currently married (n %) 120 (75) 124(76) 0.91*
Parity (mean, SD) 2.1±2.1 2.0±2.2 0.62*
Previous caesarean section 6(3.8) 5(3.1) 0.99*
Previous induced abortion (n %) 42(26.3) 44(27.5) 0.94*              
Previous spontaneous abortion (n %) 7(4.4) 6(3.8) 0.99*
Woman’s report of current abortion (n %)
Spontaneous 150(93.8) 152(95.0) 0.99*
Induced 10(6.3) 8(5) 0.82* 
*not significant
Efficacy and adverse effects: The success rates in the two 
groups (defined as not requiring a secondary surgical 
procedure) were very high and not statistically 
different (misoprostol: 98.8%, MVA: 100%, P = 0.99; 
Table 2).  The two misoprostol failures were women 
who presented at their first follow-up visit in seven 
days with retained products and requested for MVA 
to evacuate their uterus completely. Most women in 
both groups reported experiencing pain and cramps 
and this was significantly more in the MVA group 
(52.5% in the misoprostol group versus 87.5% in 
the MVA group, P <0.05). The reported mean pain 
score was significantly higher among MVA patients 
than misoprostol patients: 4.5 versus 3.0 (P<0.001). 
Women receiving misoprostol were significantly more 
likely to report bleeding in three days after treatment 
than women treated with MVA (100% versus 56.3%; 
P<0.001), and in subsequent days up to seven days 
post treatment (50% versus 6.3%; P<0.001). No patient 
reported bleeding in two weeks post treatment. 
Fever, chills, nausea, vomiting and diarrhoea were 
infrequently cited and tended to resolve within 24 
hours. Misoprostol users made more telephone calls 
to study providers than MVA users (50% versus 9.4%; 
P<0.001). 
Table 2
Efficacy and adverse effects
 Misoprostol MVA P-value
 N(%) N(%)
Success** 158(98.8) 160(100) 0.99
Failure 2(1.2) 0(0) 
Bleeding in 3 days after treatment 160(100) 90(56.3) 0.001*
Bleeding in 7 days after treatment 80(50) 10(6.3) 0.001*
Bleeding in 2 weeks after treatment 0(0) 0(0)
Pain/cramps
Ever 84(52.5) 140(87.5) 0.005*
Mean days 1.3 1.4 0.45
Fever
Ever 15(9.4) 9(5.6) 0.33                          
Mean days 1.0 1.0
Nausea
Ever 8(5) 7(4.4) 0.99
Mean days 1.0 1.0
Vomiting
Ever 6(3.8) 6(3.8) 0.77
Mean days 1.0 1.0
Chills
Ever 11(6.9) 4(2.5)
Mean days 1.0 1.0
Diarrhea 
Ever 3(1.9) 0(0)
Mean days 1.0 0(0)
**Defined as not requiring a secondary surgical procedure
*significant
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Satisfaction and acceptability: Women in both groups 
were satisfied with their treatments. Misoprostol 
users were significantly more likely to report that they 
were ‘very satisfied’ with the method (75.6% versus 
45%, P<0.001; Table 3), and three times more likely 
to inform that the adverse effect of their method of 
treatment were ‘easily tolerable’. Significantly larger 
proportions of women in the misoprostol group 
informed that they would choose that treatment again 
and would recommend it to a friend. 
Table 3
Satisfaction and acceptability
 Misoprostol MVA P-value
 N(%) N(%)
Overall satisfaction
Very satisfied 121(75.6) 72(45) <0.001*    
Satisfied 39(24.4) 88(55)
Unsatisfied or very unsatisfied 0(0) 0(0)
Tolerability of adverse effects
Bad 0(0) 0(0) <0.001*
Tolerable 64(40) 128(80)
Easily tolerable 96(60) 32(20)
Would choose method again
Yes 155(96.9) 89(55.6) <0.001*
No 5(3.1) 71(44.4)
Would recommend to a friend




This study confirms that a single dose of 600µg oral 
misoprostol is a safe, suitable, and effective alternative 
to MVA in the treatment of incomplete abortion. In 
this study, misoprostol was successful in evacuating 
the uterus in 98.8% of cases. This high success rate 
is comparable with the success rates reported by 
researchers elsewhere (6-11).  
 Women using misoprostol did not find the 
adverse effects of this method of treatment difficult 
to tolerate, perhaps because, in comparison with 
women using MVA, they experienced lower levels 
of pain and this finding is consistent with reports 
by other studies (8-11). As evidenced by greater 
willingness to choose the treatment method again and 
to recommend it to a friend, women using misoprostol 
appeared more satisfied with their treatment than 
those undergoing MVA. This is also similar to the 
observations by previous researchers (8-11) and 
confirms that misoprostol is a suitable alternative 
to MVA. In contrast to the observations by Dao et al 
(9), this study revealed that misoprostol users were 
more likely to make more phone calls to the facility 
to seek reassurance than MVA users. This might be 
because misoprostol use in postabortion care is new 
to the women some of whom have been treated 
of incomplete abortion in the past with MVA. As 
providers become comfortable with misoprostol for 
treatment of incomplete abortion, patient counselling 
will improve; the womens’ knowledge of misoprostol 
will improve and success rates will generally rise.
  The findings in this study provides further 
evidence that ultrasonography  is not essential to 
provide misoprostol for treatment of incomplete 
abortion (6,9,11) making the drug a practical 
alternative in PAC facilities lower down in the health 
system hierarchy  that may lack ultrasound equipment 
or where ultrasound is too costly.  It is unlikely that 
every healthcare facility in a rural area in Africa will 
have the resources to verify incomplete abortion status 
through ultrasound for all presenting women. Several 
recent studies in low-resource settings rarely used 
ultrasound to diagnose incomplete abortion (<5% 
of diagnoses were confirmed via ultrasound) or to 
confirm uterine evacuation (6-8, 10). Nevertheless, 
because ultrasound was not used to diagnose 
incomplete abortion, the study population may have 
included women with inevitable or already completed 
abortion.
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 Women with previous Caesarean sections were 
not excluded in this study yet misoprostol used for 
incomplete abortion treatment in these women was 
generally safe. Given that this study was conducted 
in only one PAC facility, it is difficult though to 
generalise how the method might turn out throughout 
other facilities. Expert opinion indicates there is no 
clinical reason to with  hold misoprostol for treatment 
of incomplete abortion in women with a previous 
Caesarean section (14).
 The study may seem remarkable in that none of 
the 320 women who participated was lost to follow-
up. Other similar trials which have been conducted 
in East , Central  and  West Africa had been lost to 
follow-up rates of 0 to 1.7% (6, 9, and 11).  That this 
study was conducted in a small rural community with 
a steady homogenous population may have given 
it an advantage in this respect. The issue of women 
lost to follow up is important, as a small proportion 
of misoprostol users (1 in 20) (14) will require a 
surgical completion. As the method is introduced in 
new settings, information and counselling should be 
provided to enable women to recognise the need for 
additional care and where to get it.
 Until recently, Post abortion care (PAC) 
programmes have recommended MVA for treatment 
of incomplete abortion and MVA has provided 
a highly effective means of uterine evacuation. 
However MVA requires skilled providers, sterilised 
equipment, surgical supplies, and a special room. 
MVA may also be complicated by cervical laceration, 
uterine perforation, and infrequent failure. On 
the other hand, medical methods for treatment of 
incomplete abortion require few resources and can 
be administered by low- and mid-level providers 
(14) making it a suitable alternative at the rural areas 
of developing countries where MVA may not be 
available.
 As sub-Saharan Africa continues to have the 
highest maternal mortality and morbidity rates in 
the world, a single dose of 600µg oral misoprostol as 
a suitable alternative to MVA for post-abortion care 
might make an impact on reducing maternal death 
from abortion-related complications in rural settings. 
Expansion of its use in rural settings, as well as its 
inclusion into country-wide PAC programmes, should 
be aggressively pursued. The inclusion of misoprostol 
to the essential medicines lists in many countries, 
including Ethiopia, Tanzania, Nigeria, Kenya and 
Zambia, for the treatment of incomplete abortion 
(15) is therefore a laudable development.  
 There were several limitations to the current 
study. It was a hospital based study and was not 
multi-centred. The sample size is also small. It was not 
possible to thoroughly discriminate between women 
with inevitable and already completed abortion. We 
recommend a population based multi-centred study 
to describe the suitability of misoprostol in incomplete 
abortion management in Nigeria.
In conclusion, this study affirms that for the 
treatment of first-trimester uncomplicated incomplete 
abortion at a rural facility, both MVA and 600 µg 
oral misoprostol are safe, effective, and acceptable 
treatments. Depending on availability of each method 
and the desires of individual women, either option 
may be presented to women for the treatment of 
incomplete abortion.
                                              
REFERENCES
Sepilian, V. P. and Shermer, C. D. Miscarriage. Available at 1. 
http://www.emedicinehealth.com/miscarriage/article. 
Accessed 4th May, 2012.
World Health Organization. Facts on Induced Abortion in 2. 
the United States. Available at http://www.guttmacher.org/
pub. Accessed 4th May, 2012.
Sedgh, G., Henshaw, S., Singh, S., Ahman, E. and Shah. I. H. 3. 
Induced Abortion: estimated rates and trends worldwide. 
Lancet 2007; 370: 1338-1345.
Sotiriadis, A., Makrydimas, G., Papatheodorou, S., 4. et al. 
Expectant, medical or surgical management of first-trimester 
miscarriage: A meta-analysis. Obstet.Gynecol. 2005; 105: 
1104-1113.
Sahin, H. G., Sahin, H. A. and Kocer, M. Randomised 5. 
outpatient clinical trial of medical evacuation and surgical 
curettage in incomplete miscarriage. Europ. J. Contrac. Repr. 
Health Care. 2001; 6: 141-144.
Shwekerela, B., Kalumuna, R., Kipingili, R.,6.  et al. Misoprostol 
for treatment of incomplete abortion at the regional hospital 
level: Results from Tanzania. Brit. J. Obst. Gynecol. 2007; 114: 
1363-1367.
Diop, A., Rakotovao, J., Raghavan, S., 7. et al. Comparison of two 
routes of administration for misoprostol in the treatment of 
incomplete abortion: A randomised clinical trial. Contraception. 
2009; 79: 456-462.
Bique, C., Usta, M., Debora, B., 8. et al. Comparison of 
misoprostol and manual vacuum aspiration for the treatment 
of incomplete abortion. Int. J. Gynecol. Obstet. 2007; 98: 222-
226. 
Dao, B., Blum, J., Thieba, B., 9. et al. Is misoprostol a safe, effective, 
acceptable alternative to manual vacuum aspiration for post 
abortion care? Results from a randomised trial in Burkina 
Faso, West Africa. Brit. J. Obst. Gynecol. 2007; 114: 1368-1375.
Weeks, A., Alia, G., Blum, J., 10. et al. A randomised trial of 
oral misoprostol versus manual vacuum aspiration for the 
treatment of incomplete abortion in Kampala, Uganda. Obstet. 
Gynecol. 2005; 106: 540-547.
Taylor, J., Diop, A., Blum, J., Dolo, O. and Winikoff, B. Oral 11. 
misoprostol as an alternative to surgical management for 
incomplete abortion in Ghana. Int. J. Gynecol Obstet. 2011; 
112: 40-44.
Osisioma Ngwa. Available at 12. http://www.wikipedia.org/
wiki/Osisioma Ngwa.
Likert, R. “A Technique for the Measurement of Attitudes”. 13. 
Arch Psychol. 1932; 140: 55.
Misoprostol for Treatment of Incomplete Abortion: An 14. 
Introductory Guide Book. Sheila Raghavan and Jillian Bynum 
(Eds.). Gynuity Health Projects, New York, USA. Available at 
http://www.gynuity.org. Accessed 4th May 5, 2012.
WHO, Priority Medicines for Mothers and Children, 15. 
WHO/EMP/MAR/2011.1, 2011, <http://www.who.int/ 
medicines/publications/A4prioritymedicines.pdf>, 
Accessed May 8, 2012.
EAMJ MISOPROSTOL MAY 2012.indd   177 6/11/13   1:50:49 PM
